The Beat AML Master Trial was designed to explore the feasibility of genomically driven precision medicine in patients with newly diagnosed acute myeloid leukemia. Preliminary results suggest that necessary testing can be completed within a week, and that patients matched to therapies may live longer—although survival data should be interpreted with caution.

©2020 American Association for Cancer Research.
2020
American Association for Cancer Research.
You do not currently have access to this content.